Differentiation of focal nodular hyperplasia from hepatocellular adenoma: Role of the quantitative analysis of gadobenate dimeglumine-enhanced hepatobiliary phase MRI.

scientific article published on 06 April 2015

Differentiation of focal nodular hyperplasia from hepatocellular adenoma: Role of the quantitative analysis of gadobenate dimeglumine-enhanced hepatobiliary phase MRI. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/JMRI.24897
P698PubMed publication ID25851028

P50authorThomas DecaensQ62096202
Alexis LaurentQ48141150
P2093author name stringDaniel Azoulay
Julien Calderaro
Alain Rahmouni
Alain Luciani
Frederic Pigneur
Laurence Baranes
Mélanie Chiaradia
Lambros Tselikas
Ariane Mallat
Elie-Serge Zafrani
Charlotte Costentin
Marion Roux
P2860cites workMRI features of inflammatory hepatocellular adenomas on hepatocyte phase imaging with liver-specific contrast agents.Q53099955
Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.Q53136942
Diagnosis of focal nodular hyperplasia with MRI: multicenter retrospective study comparing gadobenate dimeglumine to gadoxetate disodium.Q53154992
Ring-like enhancement of focal nodular hyperplasia with hepatobiliary-phase Gd-EOB-DTPA-enhanced magnetic resonance imaging: radiological-pathological correlation.Q53196041
Diagnostic and pathogenetic implications of the expression of hepatic transporters in focal lesions occurring in normal liver.Q54643529
Genotype–phenotype correlation in hepatocellular adenoma: New classification and relationship with HCCQ57782566
Hepatobiliary MR imaging with gadolinium-based contrast agentsQ24631773
Clinical management of benign liver cell tumorsQ33325109
Quantitative evaluation of enhancement patterns in focal solid liver lesions with Gd-EOB-DTPA-enhanced MRI.Q33784125
Imaging of hepatic steatosisQ34215183
Focal nodular hyperplasia of the liver in men: is presentation the same in men and women?Q35594682
Focal nodular hyperplasia: findings at state-of-the-art MR imaging, US, CT, and pathologic analysisQ35632208
Focal nodular hyperplasiaQ36369048
Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agentsQ37945555
Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosisQ37979150
Diagnostic accuracy of MRI in differentiating hepatocellular adenoma from focal nodular hyperplasia: prospective study of the additional value of gadoxetate disodium.Q38021747
Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image qualityQ38063463
Matched within-patient cohort study of transient arterial phase respiratory motion-related artifact in MR imaging of the liver: gadoxetate disodium versus gadobenate dimeglumineQ38195093
Imaging of benign hepatocellular lesions: current concepts and recent updatesQ38196549
Differentiation of focal nodular hyperplasia from hepatocellular adenomas with low-mechanical-index contrast-enhanced sonography (CEUS): effect of size on diagnostic confidence.Q38239629
The diagnostic value of Gd-EOB-DTPA-MRI for the diagnosis of focal nodular hyperplasia: a systematic review and meta-analysisQ38299642
Gadoxetic Acid–enhanced Hepatobiliary Phase MR Imaging: Cellular InsightQ42853997
Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteersQ43287335
Molecular mechanisms for the hepatic uptake of magnetic resonance imaging contrast agents.Q43452907
Focal nodular hyperplasia of the liver: assessment with contrast-enhanced TurboFLASH MR imagingQ44331220
Magnetic resonance imaging with hepatospecific contrast agents in cirrhotic rat liversQ46381565
Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study.Q46546726
Hepatic iron and nonalcoholic fatty liver disease.Q50516617
Liver perfusion in dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI): comparison of enhancement in Gd-BT-DO3A and Gd-EOB-DTPA in normal liver parenchyma.Q51129770
Benign liver tumors: differential diagnosis and indications for surgery.Q52253761
Inflammatory hepatocellular adenomas can mimic focal nodular hyperplasia on gadoxetic acid-enhanced MRI.Q53032344
P433issue5
P921main subjecthepatocellular adenomaQ1172076
focal nodular hyperplasiaQ1435219
P304page(s)1249-1258
P577publication date2015-04-06
P1433published inJournal of Magnetic Resonance ImagingQ15761156
P1476titleDifferentiation of focal nodular hyperplasia from hepatocellular adenoma: Role of the quantitative analysis of gadobenate dimeglumine-enhanced hepatobiliary phase MRI
P478volume42

Reverse relations

cites work (P2860)
Q48354879Differentiating focal nodular hyperplasia from hepatocellular adenoma: Is hepatobiliary phase MRI (HBP-MRI) using linear gadolinium chelates always useful?
Q49292129Efficacy comparison of multi-phase CT and hepatotropic contrast-enhanced MRI in the differential diagnosis of focal nodular hyperplasia: a prospective cohort study.
Q64117986Identification of Arterial Hyperenhancement in CT and MRI in Patients with Hepatocellular Carcinoma: Value of Unenhanced Images
Q53015861Impact of hepatobiliary phase liver MRI versus Contrast-Enhanced Ultrasound after an inconclusive extracellular gadolinium-based contrast-enhanced MRI for the diagnosis of benign hepatocellular tumors.
Q57301412Molecular classification of hepatocellular adenomas: impact on clinical practice
Q88551246Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions

Search more.